Advertisement

Reactions Weekly

, Volume 1658, Issue 1, pp 6–6 | Cite as

Selexipag contraindicated with strong CYP2C8 inhibitors

Correspondence
  • 62 Downloads

Reference

  1. Bloomfield P. Uptravi (selexipag): concomitant use with strong CYP2C8 inhibitors (e.g. gemfibrozil) now contraindicated. Internet Document : [2 pages], 14 Jun 2017. Available from: URL: http://www.hpra.ie/docs/default-source/default-document-library

Copyright information

© Springer International Publishing AG 2017

Personalised recommendations